Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome

Clinical Cancer Research

Volumn 19, Issue 12, 2013, Pages 3247-3258

  Todoerti, Katia ^a,b,d   Agnelli, Luca ^a,b   Fabris, Sonia ^a,b   Lionetti, Marta ^a,b   Tuana, Giacomo ^a,b   Mosca, Laura ^a,b   Lombardi, Luigia ^a,b   Grieco, Vitina ^c   Bianchino, Gabriella ^c   D'Auria, Fiorella ^c   Statuto, Teodora ^c   Mazzoccoli, Carmela ^d   De Luca, Luciana ^d   Petrucci, Maria Teresa ^e   Morabito, Fortunato ^f   Offidani, Massimo ^g   Raimondo, Francesco Di ^h   Falcone, Antonietta ⁱ   Omede, Paola ^j   Tassone, Pierfrancesco ^k   Boccadoro, Mario ^j   Palumbo, Antonio ^j   Neri, Antonino ^a,b   Musto, Pellegrino ^c   more..

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c Referral Cancer Center of Basilicata ^*  (Italy)

^d REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f Azienda Ospedaliera di Cosenza   (Italy)

^g OSPEDALI RIUNITI   (Italy)

^h UNIVERSITY OF CATANIA   (Italy)

ⁱ CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^j UNIVERSITY OF TURIN   (Italy)

^k UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; LENALIDOMIDE;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EXPLORATORY RESEARCH; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE LOCUS; GENE TRANSLOCATION; GENETIC ASSOCIATION; HEMATOLOGICAL PARAMETERS; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN HEAVY CHAIN GENE; KIDNEY FUNCTION; MICROARRAY ANALYSIS; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; NUCLEOTIDE SEQUENCE; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTOMICS;

CLINICAL TRIALS AS TOPIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, PLASMA CELL; PATHOLOGY, MOLECULAR; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TRANSCRIPTION, GENETIC; TRANSCRIPTOME; TREATMENT OUTCOME;

EID: 84879464790     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3461     Document Type: Article

References (37)

1. Albarracin F, Fonseca R. Plasma cell leukemia. Blood Rev 2011;25: 107-12.
2. Avet-Loiseau H, Daviet A, Brigaudeau C, Callet-Bauchu E, Terre C, Lafage-Pochitaloff M, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood 2001;97:822-5.
3. Chang H, Qi X, Yeung J, Reece D, Xu W, Patterson B. Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leuk Res 2009;33:259-62.
4. Chang H, Sloan S, Li D, Patterson B. Genomic aberrations in plasma cell leukemia shown by interphase fluorescence in situ hybridization. Cancer Genet Cytogenet 2005;156:150-3.
5. Chiecchio L, Dagrada GP, White HE, Towsend MR, Protheroe RK, Cheung KL, et al. Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosomes Cancer 2009;48:624-36.
6. Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T, Van Wier SA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008;22:1044-52.
7. Perez-Andres M, Almeida J, Martin-Ayuso M, Moro MJ, Martin-Nunez G, Galende J, et al. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia 2005;19:449-55.
8. Mattioli M, Agnelli L, Fabris S, Baldini L, Morabito F, Bicciato S, et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 2005;24:2461-73.
9. Usmani SZ, Nair B, Qu P, Hansen E, Zhang Q, Petty N, et al. Primary plasma cell leukemia: clinical and laboratory presentation, geneexpression profiling and clinical outcome with Total Therapy protocols. Leukemia 2012.
10. Bird JM, Owen RG, D'Sa S, Snowden JA, Pratt G, Ashcroft J, et al. Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 2011;154:32-75.
11. van de Donk NW, Lokhorst HM, Anderson KC, Richardson PG. How I treat plasma cell leukemia. Blood 2012;120:2376-89.
12. Mosca L, Musto P, Todoerti K, Barbieri M, Agnelli L, Fabris S, et al. Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. Am J Hematol 2013;88:16-23.
13. Agnelli L, Forcato M, Ferrari F, Tuana G, Todoerti K, Walker BA, et al. The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma. Clin Cancer Res 2011;17:7402-12.
14. Agnelli L, Bicciato S, Mattioli M, Fabris S, Intini D, Verdelli D, et al. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. J Clin Oncol 2005;23:7296-306.
15. Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K, et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res 2007;67:2982-9.
16. Gutierrez NC, Ocio EM, de Las RJ, Maiso P, Delgado M, Ferminan E, et al. Gene expression profiling of B lymphocytes and plasma cells from Waldenstrom's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 2007; 21:541-9.
17. Lombardi L, Poretti G, Mattioli M, Fabris S, Agnelli L, Bicciato S, et al. Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease. Genes Chromosomes Cancer 2007;46:226-38.
18. Agnelli L, Mosca L, Fabris S, Lionetti M, Andronache A, Kwee I, et al. A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. Genes Chromosomes Cancer 2009;48: 603-14.
19. Agnelli L, Fabris S, Bicciato S, Basso D, Baldini L, Morabito F, et al. Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma. Br J Haematol 2007;136:565-73.
20. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
21. Goeman JJ, van de Geer SA, de KF, van Houwelingen HC. A global test for groups of genes: testing association with a clinical outcome. Bioinformatics 2004;20:93-9.
22. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, et al. Frequent engagement of the classical and alternative NFkappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007;12:115-30.
23. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007;12:131-44.
24. Hose D, Reme T, Hielscher T, Moreaux J, Messner T, Seckinger A, et al. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica 2011;96:87-95.
25. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005;106:296-303.
26. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood 2006;108:2020-8.
27. Croonquist PA, Van Ness B. The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene 2005;24: 6269-80.
28. Decaux O, Lode L, Magrangeas F, Charbonnel C, Gouraud W, Jezequel P, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in lowrisk patients: a study of the Intergroupe Francophone du Myelome. J Clin Oncol 2008;26:4798-805.
29. Dickens NJ, Walker BA, Leone PE, Johnson DC, Brito JL, Zeisig A, et al. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin Cancer Res 2010;16:1856-64.
30. Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;109:2276-84.
31. Azab AK, Azab F, Blotta S, Pitsillides CM, Thompson B, Runnels JM, et al. RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. Blood 2009;114:619-29.
32. Qiang YW, Walsh K, Yao L, Kedei N, Blumberg PM, Rubin JS, et al. Wnts induce migration and invasion of myeloma plasma cells. Blood 2005;106:1786-93.
33. van de Donk NW, Lokhorst HM, Nijhuis EH, Kamphuis MM, Bloem AC. Geranylgeranylated proteins are involved in the regulation of myeloma cell growth. Clin Cancer Res 2005;11:429-39.
34. Landowski TH, Olashaw NE, Agrawal D, Dalton WS. Cell adhesionmediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. Oncogene 2003;22: 2417-21.
35. Guo F, Sun A, Wang W, He J, Hou J, Zhou P, et al. TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells. Mol Immunol 2009;46: 2441-8.
36. Glauner H, Siegmund D, Motejadded H, Scheurich P, Henkler F, JanssenO, et al. Intracellular localization and transcriptional regulation of tumor necrosis factor (TNF) receptor-associated factor 4 (TRAF4). Eur J Biochem 2002;269:4819-29.
37. Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW, et al. The anticancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 2009;77:78-86. Ricerca